Abstract: The present technology provides crystalline free base and crystalline hydrochloride, hydrobromide, edisylate, and mesylate salts of (R)-2-(4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methyl)-2-methylpiperazin-1-yl)-4-methoxybenzo[d]thiazole-6-carboxylic acid. The present technology further provides methods for preparing the various forms, compositions containing them, and methods related to modulation of FXR. In particular, the present crystalline compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., hepatitis B, liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, and atherosclerosis, and renal disease.

Abstract: The present technology provides crystalline free base and crystalline hydrochloride, hydrobromide, edisylate, and mesylate salts of (R)-2-(4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methyl)-2-methylpiperazin-1-yl)-4-methoxybenzo[d]thiazole-6-carboxylic acid. The present technology further provides methods for preparing the various forms, compositions containing them, and methods related to modulation of FXR. In particular, the present crystalline compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., hepatitis B, liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, and atherosclerosis, and renal disease.

Abstract: The present invention discloses compounds of Formula (I) as novel ligand conjugates, and use thereof for delivering therapeutically active agents. The compounds of the present invention have the advantages for in vitro and/or in vivo delivery of therapeutically active agents, e.g., iRNA agents.

Abstract: The present invention is directed to compounds of formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and methods related to agonists of glucagon-like peptide-1 receptor (GLP-1R). In particular, the compounds and compositions may be used to treat GLP-1R-related disorders and conditions, including, e.g., obesity, T2DM, NAFLD, NASH as disclosed herein.

Abstract: The present technology is directed to compounds, compositions, and methods related to modulation of MNK. In particular, the present compounds and compositions may be used to treat MNK-mediated disorders and conditions, including, e.g., various solid and hematological cancers.